Capital Gains

Every so often, the industry pauses to recognize leadership in a different light. The 2026 Healthcare Businesswomen’s Association (HBA) Woman of the Year does exactly that. As noted in this issue’s Pharmaceutical Executive feature profile, Dr. Aradhana Sarin, executive director and chief financial officer (CFO) of AstraZeneca, is the first finance chief to receive the honor. And that alone says something about where biopharma is headed. Leadership today, most will agree, isn’t, or shouldn’t be, defined by function — but rather by impact.

What stands out in Sarin’s story, and in our April profile, is the range. A physician by training who pivoted into investment banking before ultimately stepping into one of the most influential CFO roles in the industry, she represents a modern kind of leadership. A convergence, if you will, that connects science, strategy and capital with equal fluency.

That perspective shows up in how she talks about the job. Yes, there’s the familiar tension — delivering short-term results while investing for the long term. But in biopharma, that balance carries higher stakes. Development cycles stretch years. Innovation demands sustained capital. And the expectations — from investors, patients and policymakers alike — rarely wait. Sarin’s approach is both pragmatic and expansive. She doesn’t see finance as a silo but as a lens across the business.

There’s also a broader signal here. As Sarin herself notes, recognition like this reflects how far the industry has come — and how much further it can go — in expanding leadership pathways.

We hope you enjoy reading about Sarin’s journey inside. On behalf of MJH Life Sciences, I extend a big congratulations to her and all of this year’s HBA award winners.

Mike Hennessy Jr. is Chairman and CEO of MJH Life Sciences^®